PureTech

PureTech is a leading clinical stage biotherapeutics incubator and platform dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases. Its incubated companies include VIP III portfolio company Gelesis.

PureTech

PureTech is a leading clinical stage biotherapeutics incubator and platform dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases. Its incubated companies include VIP III portfolio company Gelesis.

  • 9 incubated companies including VIP III portfolio company Gelesis and 24 product candidates of which 13 are clinical stage and two have FDA and European Regulatory Clearances
  • Wholly-owned pipeline of 3 clinical-stage drug candidates and a further 3 drug platforms specialising in the Brain, Immune, Gut interface
  • Proven track record of clinical trial success with above industry average probabilities, particularly notable in stages where industry failures are typically high
  • Significant recent milestones including monetisation, FDA approvals, and incubated company fundraisings

Key facts

  1. Sales Not Disclosed
  2. Employees 60 (2019, excluding incubated companies)
  3. Industry Life Sciences & Healthcare
  4. Headquarters North America
  5. Geographic Footprint North America
  6. Website puretechhealth.com
  7. Investment Date September 2020
  8. Fund VIP III Cortex

Investment Facts

PureTech

PureTech is a leading clinical stage biotherapeutics incubator and platform dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases. Its incubated companies include VIP III portfolio company Gelesis.

Key facts

  1. Sales Not Disclosed
  2. Employees 60 (2019, excluding incubated companies)
  3. Industry Life Sciences & Healthcare
  4. Headquarters North America
  5. Geographic Footprint North America
  6. Website puretechhealth.com
  7. Investment Date September 2020
  8. Fund VIP III Cortex
  • 9 incubated companies including VIP III portfolio company Gelesis and 24 product candidates of which 13 are clinical stage and two have FDA and European Regulatory Clearances
  • Wholly-owned pipeline of 3 clinical-stage drug candidates and a further 3 drug platforms specialising in the Brain, Immune, Gut interface
  • Proven track record of clinical trial success with above industry average probabilities, particularly notable in stages where industry failures are typically high
  • Significant recent milestones including monetisation, FDA approvals, and incubated company fundraisings

Back